HVTN 114
Status:Completed
Phase:I
Principal Investigator(s):Harriet L. Robinson, GeoVax
Objective:To evaluate the immunogenicity of AIDSVAX® B/E bivalent gp120 vaccine and MVA/HIV62B in healthy, HIV-1 uninfected adult participants who previously received MVA/HIV62B in DNA/MVA or MVA/MVA regimens in HVTN 205.
March 24, 2021
Prevention Option(s):HIV Vaccine
Study Design:Double-blind, Randomized
Arms and Assigned Interventions
DescriptionHVTN 114 w GeoVax MVA62B vaccine with or without a gp120 protein vaccine, AIDSVAX® B/E
Mode of Delivery
ARMsExperimental
Official Code:
NCT02852005
Trial Sponsors:
HVTN
Start Date
End Date
January 2, 2017
October 29, 2019
Enrollment:27
Age range:
18 Years ↔
55 Years
Population: